PEL

The Exchange has sought clarification from Piramal Enterprises Limited with respect to recent news item captioned "Piramal to Hold 35% in Combo Entity with IL&FS". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any infor

Piramal Enterprises Limited has informed the Exchange regarding a clarification on a news item captioned "Piramal exists Omkar's Mumbai Project". The Company has clarified that "The investment of INR 200 crores in the Omkar project referred to in the news article, was made by the Indiareit Domestic Scheme IV which is managed and advised by Piramal Fund Management Private Limited (wholly owned subsidiary of the Company) ('PFMPL'). The investment was not made by PFMPL, nor by the Company. PFMPL is the Investment Manager of Indiareit Domestic Scheme IV. Both the investment referred to above and t

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a news item captioned "Piramal Likely to Hive Off Its Critical Care Business". The Company has clarified that "As part of its strategy, the Company continually evaluates strategic initiatives with the objective of adding value to its shareholders. As per established practice, only those initiatives that are definitive and which are disclosable events, are disclosed to the Stock Exchanges. In this regard, the Company would like to clarify that there is no such proposal as referred to in the captioned news art

The Exchange has sought clarification from Piramal Enterprises Limited with respect to recent news item captioned "Piramal Likely to Hive Off Its Critical Care Business". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of an

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a news item captioned "Piramal may buy Apollo's Health Super HiWay". The Company has clarified that "As part of its growth strategy, the Company continually looks at strategic initiatives including viable investment opportunities. All of these are channelled towards achieving operational excellence and growth. So far as the captioned news article is concerned, the Company's proposed investment in Health Super HiWay is subject to several pre-conditions, only upon fulfillment of which, the investment would be

The Exchange has sought clarification from Piramal Enterprises Limited with respect to recent news item captioned "Piramal May Buy Apollo's Health Super HiWay". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any informat

Spurt in Volume : Substantial increase in trading volumes have been observed in Piramal Enterprises Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Enterprises Limited has vide its letter inter-alia stated, "We would like to clarify that we are not aware of such information/announcement (including impending announcement)."

The Exchange had sought clarification from Piramal Enterprises Limited with respect to an announcement dated January 16, 2015, regarding a press release dated January 15, 2015 titled "Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc". The Company has clarified as follows: 1. Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof; Reply: As mentioned in the Press Release, no related party of Piramal Enterprises Limited (i

The Exchange has sought clarification from Piramal Enterprises Limited with respect to an announcement dated January 16, 2015, regarding a press release dated January 15, 2015 titled "Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc". On basis of above the Company is required to clarify following: 1. Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof; 2. Nature of consideration - whether cash consideration or share s

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a recent news item captioned "Piramal's pharma arm to invest $40m in new tech". The Company has clarified that "As part of its strategy, the Company's Pharma Solutions division continually looks at viable investment opportunities for augmenting its existing capacity and adding new capabilities, including by way of adding new equipments and incorporating new technologies. All of these are channelled towards achieving operational excellence and growth. Recently, the Company has completed a series of these ini

The Exchange has sought clarification from Piramal Enterprises Limited with respect to recent news item captioned "Piramal's pharma arm to invest $40 m in new tech". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any inf

The Exchange has sought clarification from Piramal Enterprises Limited with respect to a news item captioned "Piramal Enterprises have acquired 2 BOT Infra Projects from Supreme Infra worth Rs. 700 crores". The Company has clarified that "The Company from time to time explores various investment opportunities as part of its structured investment business, in the normal course of its business. This evaluation of opportunities includes various criteria, including technical, financial, taxation, commercial, regulatory and legal. Once these criteria are met, it is followed by internal approvals at

Piramal Enterprises Limited has informed the Exchange with reference to news item appearing in the newspaper titled "Piramal Leads Race for 3 Ramky Highway Projects". "In this regard, we would like to state that the Company from time to time explores various investment opportunities as part of its structured investment business, in the normal course of its business. Not all of these result in definitive actions, and may or may not necessarily result into transactions. Hence, any comment by us on speculative reports, without any disclosable event having taken place, could potentially impact

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a news item captioned "DiaSys to buy Piramal's diagnostic business". The Company has clarified that "The Company has signed an agreement for sale of its Lab Diagnostics & Point of Care Business to Diasys Diagnostics India Private Limited, for a consideration of Rs. 13.00 crores. In addition, the Company would be transferring related technology for a consideration of Rs. 0.30 crores. It is relevant to note here that this business, comprising buying and selling of diagnostic equipments, serving large pathologi

The Exchange sought clarification from Piramal Enterprises Limited with respect to news item captioned "Piramal to exit drug discovery business". The Company has clarified that "The Company has only decided to scale back its investments in NCE R&D activity in Mumbai. We would like to clarify that New Chemical Entity Research (NCE R&D) is only a part of the Company s R&D Activity, which also encompasses research in Radiopharmaceuticals, Anesthesia and Pharma Solutions, which have a relatively higher likelihood of success, as against the NCE R&D where the pipeline of projects are at early st

The Exchange had sought clarification from Piramal Enterprises Limited with respect to a news item captioned "Piramal Enterprises seeks to sell diagnostic solution business". The Company has clarified that "As a fast growing Company, Piramal Enterprises Limited explores various business and strategic initiatives from time to time, keeping in mind its business focus, strategic interests and the economic environment, amongst other factors. As a policy and in the interest of its shareholders, the Company does not comment on any report / news article such as the one referred to in your email, whic

News Verification : The media had reports that Piramal Healthcare Limited is in talks with Ind-Swift Laboratories Limited to acquire contract research and manufacturing business. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Healthcare Limited has vide its letter inter-alia stated, " We would like to clarify that as a fast growing company, Piramal Enterprises Limited (Formerly known as Piramal Healthcare Limited) explores

News Verification : The media had reports that Piramal Healthcare Limited may buy Mafatlal Industries Limited's 7 acre plot in Central Mumbai. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Healthcare Limited has vide its letter inter-alia stated, "We would like to clarify that the said news article does not pertain at all to the Company. The Company is not buying any land from Mafatlal Industries Limited."

News Verification : The media had reports that Piramal Healthcare Limited. may merge Piramal Lifesciences Limited with itself. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Healthcare Limited has vide its letter inter-alia stated, "We would like to state that the Company explores various strategic moves from time to time. However, as a policy and in the interest of its shareholders, the Company does not comment on any rep

News Verification : The media had reports that Pfizer Limited may buy a controlling stake in Piramal Healthcare Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Piramal Healthcare Limited has vide its letter inter-alia stated," We hereby confirm that there is no proposal by the Promoter for selling any stake in the Company."

Piramal Healthcare Limited has informed the Exchange with reference to the earlier announcement dated September 10, 2009 on Pledge of Shares - Disclosure u/s 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 1997 as follows: "In view of the queries being received and to avoid confusion, we wish to clarify that the total shares pledged by the entity viz. PHL Holdings Pvt Ltd (i.e.84,20,000 shares), which is one of the constituents of the Promoter Group, constitute only 8.13% of the Promoter Group Shareholding in Piramal Healthcare Limited".

News Verification : The media had reports that Sanofi-Aventis may buy a substantial stake in the company. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Piramal Healthcare Limited has vide its letter inter-alia stated,"We would like to clarify that the promoter has no intention to dilute current ownership levels."

Clarification of News : The press had reports on November 15, 2005 that Nicholas Piramal India Limited may acquire Germany's generic firm betapharm Arzneimittel. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Nicholas Piramal India Ltd. has vide its letter inter-alia stated, "In this regard, we wish to clarify that the Company explores various strategic moves from time to time. However, as a policy and in the inte

News Verification : The press had reports on October 28, 2004 that Nicholas Piramal India Limited expects to ink four outsourcing deals and is also in the process of setting up a finished drugs manufacturing facility at Baddi, Himachal Pradesh, at an estimated Rs. 140 crore. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Nicholas Piramal India Limited has vide its letter inter-alia stated, "The Company expects to

News Verification : The press had reports that Nicholas Piramal India Limited expects to ink four outsourcing deals and is also in the process of setting up a finished drugs manufacturing facility at Baddi, Himachal Pradesh, at an estimated Rs. 140 crore. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Nicholas Piramal India Limited.

Clarification of News : The press had reports that Nicholas Piramal India Ltd. might declare a bonus.The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Nicholas Piramal India Ltd. has vide its letter inter-alia stated, "We would like to inform that there is no such proposal for issue of bonus shares under consideration by the Board ".